Evogene Ltd Ord (EVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | -958 | 1,740 | 605 | 4,190 | 578 |
| Cost of Goods | 692 | 1,042 | 336 | 310 | 398 |
| Gross Profit | -1,650 | 698 | 269 | 3,880 | 180 |
| Operating Expenses | 3,211 | 6,660 | 5,234 | 8,276 | 8,206 |
| Operating Income | -4,169 | -5,920 | -4,629 | -4,086 | -7,628 |
| Interest Expense | 206 | 2,889 | 97 | 166 | 71 |
| Other Income | 4,711 | 2,062 | 174 | 407 | 358 |
| Pre-tax Income | 336 | -6,747 | -4,552 | -3,845 | -7,341 |
| Income Tax | 7 | 1 | 1 | N/A | -4 |
| Net Income Continuous | 1,761 | -6,748 | -5,985 | -3,845 | -7,337 |
| Net Income Discontinuous | -1,766 | -1,471 | N/A | N/A | N/A |
| Minority Interests | -432 | -589 | -566 | 18 | -736 |
| Net Income | $427 | $-7,630 | $-5,419 | $-3,863 | $-6,601 |
| EPS Basic Total Ops | 0.24 | -1.31 | -1.06 | -0.76 | -1.21 |
| EPS Basic Continuous Ops | 0.49 | -1.16 | -1.18 | -0.76 | -1.33 |
| EPS Basic Discontinuous Ops | -0.31 | -0.25 | N/A | N/A | N/A |
| EPS Diluted Total Ops | 0.24 | -1.31 | -1.06 | -0.76 | -1.21 |
| EPS Diluted Continuous Ops | 0.49 | -1.16 | -1.18 | -0.76 | -1.33 |
| EPS Diluted Discontinuous Ops | -0.31 | -0.25 | N/A | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | 0.06 | -1.31 | -1.06 | N/A | N/A |
| EBITDA(a) | $-3,394 | $-5,574 | $-4,569 | $-3,415 | $-6,965 |